Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

1.

Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.

Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B, Hamblett N, Heald AE.

Chest. 2004 Feb;125(2):509-21.

PMID:
14769732
[PubMed - indexed for MEDLINE]
2.

Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.

Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, Spencer LT, Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Carter BJ, Martin DB, Heald AE.

Hum Gene Ther. 2007 Aug;18(8):726-32.

PMID:
17685853
[PubMed - indexed for MEDLINE]
3.

A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease.

Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, McNamara SC, Gibson RL, Ramsey BW, Carter BJ, Reynolds TC.

Hum Gene Ther. 2001 Oct 10;12(15):1907-16.

PMID:
11589832
[PubMed - indexed for MEDLINE]
4.

A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies.

Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP, Dimiceli S, Brown BW, Desch JK, Norbash AM, Conrad CK, Guggino WB, Flotte TR, Wine JJ, Carter BJ, Reynolds TC, Moss RB, Gardner P.

Hum Gene Ther. 2002 Jul 20;13(11):1349-59.

PMID:
12162817
[PubMed - indexed for MEDLINE]
5.

Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications.

Joseph PM, O'Sullivan BP, Lapey A, Dorkin H, Oren J, Balfour R, Perricone MA, Rosenberg M, Wadsworth SC, Smith AE, St George JA, Meeker DP.

Hum Gene Ther. 2001 Jul 20;12(11):1369-82.

PMID:
11485629
[PubMed - indexed for MEDLINE]
6.

Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study.

Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S, Conrad CK, Brass-Ernst L, Humphries M, Sullivan K, Wetzel R, Taylor G, Carter BJ, Guggino WB.

Hum Gene Ther. 2003 Jul 20;14(11):1079-88.

PMID:
12885347
[PubMed - indexed for MEDLINE]
7.

Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.

Wagner JA, Messner AH, Moran ML, Daifuku R, Kouyama K, Desch JK, Manley S, Norbash AM, Conrad CK, Friborg S, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner P.

Laryngoscope. 1999 Feb;109(2 Pt 1):266-74.

PMID:
10890777
[PubMed - indexed for MEDLINE]
8.

A double-blind, placebo controlled, dose ranging study to evaluate the safety and biological efficacy of the lipid-DNA complex GR213487B in the nasal epithelium of adult patients with cystic fibrosis.

Knowles MR, Noone PG, Hohneker K, Johnson LG, Boucher RC, Efthimiou J, Crawford C, Brown R, Schwartzbach C, Pearlman R.

Hum Gene Ther. 1998 Jan 20;9(2):249-69.

PMID:
9472784
[PubMed - indexed for MEDLINE]
9.

Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung.

Conrad CK, Allen SS, Afione SA, Reynolds TC, Beck SE, Fee-Maki M, Barrazza-Ortiz X, Adams R, Askin FB, Carter BJ, Guggino WB, Flotte TR.

Gene Ther. 1996 Aug;3(8):658-68.

PMID:
8854091
[PubMed - indexed for MEDLINE]
10.

Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial.

Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL, Phillips J, Davies J, Smith SN, Browning J, Davies MG, Hodson ME, Durham SR, Li D, Jeffery PK, Scallan M, Balfour R, Eastman SJ, Cheng SH, Smith AE, Meeker D, Geddes DM.

Lancet. 1999 Mar 20;353(9157):947-54.

PMID:
10459902
[PubMed - indexed for MEDLINE]
11.

Evaluation of exposure and health care worker response to nebulized administration of tgAAVCF to patients with cystic fibrosis.

Croteau GA, Martin DB, Camp J, Yost M, Conrad C, Zeitlin PL, Heald AE.

Ann Occup Hyg. 2004 Nov;48(8):673-81. Epub 2004 Oct 26.

PMID:
15507460
[PubMed - indexed for MEDLINE]
Free Article
12.

Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.

Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, Mathews D, Gorden J, Schaberg A, Williams J, Ramsey B; Cystic Fibrosis Foundation Therapeutics Development Network.

Pediatr Pulmonol. 2005 Apr;39(4):339-48.

PMID:
15704203
[PubMed - indexed for MEDLINE]
13.

Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution.

Konstan MW, Davis PB, Wagener JS, Hilliard KA, Stern RC, Milgram LJ, Kowalczyk TH, Hyatt SL, Fink TL, Gedeon CR, Oette SM, Payne JM, Muhammad O, Ziady AG, Moen RC, Cooper MJ.

Hum Gene Ther. 2004 Dec;15(12):1255-69.

PMID:
15684701
[PubMed - indexed for MEDLINE]
14.

[Aerosol administration of a replication defective recombinant adenovirus expressing normal human cDNA-CFTR in the respiratory tractus in patients with cystic fibrosis].

Bellon G, Calmard L, Thouvenot D, Levrey H, Jagneaux V, Poitevin F, Malcus C, Accart N, Séné C, Layani MP, Aymard M, Bienvenu J, Courtney M, Döring G, Gilly B, Gilly R, Lamy D, Morel Y, Paulin C, Perraud F, Rodillon L, So S, Touraine F, Schatz C, Pavirani A.

C R Seances Soc Biol Fil. 1996;190(1):109-42. French.

PMID:
8881273
[PubMed - indexed for MEDLINE]
15.

Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.

Lee T, Southern KW.

Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005599. Review. Update in: Cochrane Database Syst Rev. 2012;10:CD005599.

PMID:
17443603
[PubMed - indexed for MEDLINE]
16.

Calculating expected lung deposition of aerosolized administration of AAV vector in human clinical studies.

Leung K, Louca E, Munson K, Dutzar B, Anklesaria P, Coates AL.

J Gene Med. 2007 Jan;9(1):10-21.

PMID:
17154340
[PubMed - indexed for MEDLINE]
17.

Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.

Lee TW, Southern KW.

Cochrane Database Syst Rev. 2013 Nov 26;11:CD005599. doi: 10.1002/14651858.CD005599.pub4. Review.

PMID:
24282073
[PubMed - indexed for MEDLINE]
18.

Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus.

Harvey BG, Leopold PL, Hackett NR, Grasso TM, Williams PM, Tucker AL, Kaner RJ, Ferris B, Gonda I, Sweeney TD, Ramalingam R, Kovesdi I, Shak S, Crystal RG.

J Clin Invest. 1999 Nov;104(9):1245-55.

PMID:
10545523
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis.

Hyde SC, Southern KW, Gileadi U, Fitzjohn EM, Mofford KA, Waddell BE, Gooi HC, Goddard CA, Hannavy K, Smyth SE, Egan JJ, Sorgi FL, Huang L, Cuthbert AW, Evans MJ, Colledge WH, Higgins CF, Webb AK, Gill DR.

Gene Ther. 2000 Jul;7(13):1156-65.

PMID:
10918483
[PubMed - indexed for MEDLINE]
Free Article
20.

Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study.

Noone PG, Hamblett N, Accurso F, Aitken ML, Boyle M, Dovey M, Gibson R, Johnson C, Kellerman D, Konstan MW, Milgram L, Mundahl J, Retsch-Bogort G, Rodman D, Williams-Warren J, Wilmott RW, Zeitlin P, Ramsey B; Cystic Fibrosis Therapeutics Development Research Group.

Pediatr Pulmonol. 2001 Aug;32(2):122-8.

PMID:
11477729
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk